Home > News > First Protein-Bound Nanoparticle Breast Cancer Drug
January 7th, 2005
First Protein-Bound Nanoparticle Breast Cancer Drug
Researchers at Lynn Sage Comprehensive Breast Center played a significant role in the U.S. Food and Drug Administration (FDA) approval of ABRAXANE(TM) (paclitaxel protein bound particles for injectable suspension), indicated for the treatment of metastatic breast cancer.
"This approval means that women with metastatic breast cancer no longer need to endure the toxicities associated with solvents and will no longer need steroid premedication when they receive this albumin-bound form of paclitaxel.
Nanoparticle Delivers Large Protein Complex to Cancer Cell Nucleus May 20th, 2013
Protein 'Passport' Helps Nanoparticles Get Past Immune System May 20th, 2013
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Imec and GLOBALFOUNDRIES collaborate to advance high-density memory technology: STT-MRAM offers enhanced performance and scalability for embedded and standalone applications May 21st, 2013
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013
Iran to Hold 1st Conference on Applications of Nanotechnology in Energy Industry May 21st, 2013